Cellevat3d® nanofiber products overview
Cellevat3d® nanofiber
microcarriers for lentiviral vector production

Cellevat3d® VAX nanofiber microcarriers for viral vaccine production


We are on the brink of a biomanufacturing revolution
The emergence of therapeutical biologics like cell- and gene therapy marks the beginning of a new medical era, revolutionizing treatment across several fields and offering options for previously untreatable diseases. While the field has grown rapidly and is expected to continue expanding, challenges in manufacturing, such as low productivity, poor yields, and scaling issues, drive up costs and limits patient access. It has been noted that these high development cost could stall the market unless a second “Biomanufacturing Revolution” follows, highlighting the urgent need for new disruptive, scalable, and sustainable technologies to make these therapies more affordable.1
The vaccine market faces similar pressures, with established upstream techniques for adherent viral vaccine production struggling to meet demands for cost-effective, scalable, and sustainable manufacturing. This challenge is amplified for large populations, the growing veterinary sector, and emerging uses such as oncolytic cancer vaccines. New methods that deliver higher titers, simplify processes, and enable rapid, robust scale-up, ideally using natural, biodegradable materials, will be essential for the next breakthrough in vaccine manufacturing.
1) World Economic Forum. Accelerating the Biomanufacturing Revolution. Whitepaper. Feb 2022
Driven by innovative cell culture technologies
As the search for more affordable therapies intensifies, so does the quest for novel cell culture technologies aimed to improve yield, overall productivity and decrease cost of production. The microcarrier market is one of the fastest growing in the industry, projected to rise from EUR 3.6 billion in 2025 to an estimated EUR 5 billion by 2030.
Cellevate is responding to exactly these needs by offering innovative cell culture products readily scalable from lab- to production-scale. These products are designed for highest yield and enhanced productivity.
The use of Cellevat3d® nanofibers provides a high surface area and enables controlled formation of three-dimensional (3D) spheroids from anchorage-dependent cells, resulting in dense, viable cell populations ideal for efficient virus propagation and production. Moreover, the nanofiber microcarriers are fully compatible with existing stainless steel and single-use stirred tank bioreactors, facilitating seamless process transfer and scale-up within existing production facilities.
Cellevat3d® nanofiber microcarriers in upstream bioprocessing applications
| Material | Cellulose-based nanofiber |
| Format | Monofibers |
| Bioreactor | Stirred tank bioreactors |
| Application | Viral vectors LV and AAV, viral vaccines, iPSCs, recombinant proteins, and organoids |

Advantages of Cellevat3d® products
|
Cellevat3d® product features |
Advantages |
|---|---|
| Up to 85% reduction in viral production costs |
High viral titers Reduced waste Reduced water use Faster bioprocessing time Enhanced prductivity |
| 3 to 13.5-fold increase in viral titers compared to current solutions | Improved yields and productivity of viral vectors and viral vaccines |
| Large surface area for adherent cells | Cell-dense spheroid cultures with high viability |
| Consistent cell growth across different bioreactor scales | Proven scalability in stirred-tank bioreactors |
| Enzyme-free cell passages | Easy and rapid seed-train expansion |
| Versatility in raw material, nanofiber size, surface functionalization, scaffold architecture, bioreactor compatibility and application areas | Flexibility to meet varying process needs |
| Ease of use | Depth filtration removal – no change to USP & DSP steps |
| Based on cellulose: biodegradable, sustainable, and green raw material | Sustainability |
| ISO 9001 and GMP manufacturing | High quality |



